| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AZD6482 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | SNS-032 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | GW 441756 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | AM-580 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | PD-0325901 | GDSC1000 | pan-cancer | AAC | 0.097 | 0.003 |
| mRNA | A-770041 | GDSC1000 | pan-cancer | AAC | -0.16 | 0.004 |
| mRNA | ZSTK474 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.005 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.11 | 0.005 |
| mRNA | tigecycline | CTRPv2 | pan-cancer | AAC | 0.13 | 0.005 |
| mRNA | GW843682X | GDSC1000 | pan-cancer | AAC | -0.15 | 0.006 |